Reclassifying Cannabis? Implications for Recreational/Medical Marijuana Use, Research, Drug Policy

Why It Matters

Rescheduling cannabis to Schedule III could transform the industry’s tax, banking, and research landscape while confronting entrenched racial inequities in drug policy.

Key Takeaways

• Rescheduling to Schedule III nears after legal reinterpretation
• Medical community sees cannabis as safer than alcohol or tobacco
• Schedule III could eliminate IRS Code 280E tax penalty
• Banking, state reforms, and international policy may shift gradually
• Racial equity concerns persist despite potential regulatory benefits

Summary

The Harvard‑hosted webinar examined the federal effort to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Panelists traced the historical attempts—legislative bills, lawsuits, and recent executive actions—highlighting President Trump’s 2025 executive order and Attorney General Merrick Garland’s pending rule, which would finally recognize a "currently accepted medical use" for marijuana.

Key insights centered on the statutory criteria for scheduling: medical utility, abuse potential, and safety. A 2022 reinterpretation by HHS broadened the definition of medical use to include state‑level legalization and physician prescribing, overturning the earlier FDA‑approval standard that had blocked rescheduling. Experts noted that this shift, coupled with growing clinical experience and emerging research, underpins the push toward Schedule III.

Panelists offered vivid examples: Dr. Peter Ginspoon contrasted cannabis’s relative safety with tobacco and alcohol, arguing that criminalization is a war‑on‑drugs artifact. Lawyer Hersh Jane quantified the economic impact, noting that Schedule III would repeal IRS Code 280E, lowering costs and curbing illicit market demand. Activist Epha Taio Harvey warned that rescheduling alone won’t resolve racial disparities, emphasizing the need for broader policy reforms.

The implications are profound. Schedule III status would unlock banking services, enable tax deductions, and catalyze state‑level reforms, while also reshaping international drug‑policy dialogues. For investors, clinicians, and policymakers, the move signals a transition from prohibition to regulated medical market, with potential to accelerate research, reduce stigma, and address longstanding equity concerns.

Original Description

In late 2025, President Trump signed an Executive Order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.

If finalized, the reclassification would mark a significant policy shift with concrete legal, economic, and research implications. What does this mean for recreational/medical use, state and federal drug law, and cannabis research?

A panel of experts moderated by Mason Marks, senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, brought multidisciplinary perspectives to this complicated issue.

Panelists:

- Dr. Peter Grinspoon, Primary care physician, cannabis and addiction specialist, Massachusetts General Hospital; Instructor, Harvard Medical School

- Ifetayo Harvey, executive director, People of Color Psychedelic Collective; POPLAR affiliated researcher, Petrie-Flom Center, Harvard Law School

- Hirsh Jain ‘12, CEO, Ananda Strategy; vice chair, Cannabis Chamber of Commerce

- Robert Mikos, professor, Vanderbilt Law School; POPLAR affiliated researcher, Petrie-Flom Center, Harvard Law School

0:00 Susanna Baruch introduction

3:15 Mason Marks introduction

5:00 Rob Mikos remarks

7:35 Peter Grinspoon remarks

9:35 Ifetayo Harvey remarks

10:55 Hirsh Jain remarks

13:25 Discussion and Q&A

59:48 Closing remarks

More on the Petrie-Flom Center: https://petrieflom.law.harvard.edu/

Learn about POPLAR: https://petrieflom.law.harvard.edu/the-project-on-psychedelics-law-and-regulation-poplar/

Visit Harvard Law Today: https://hls.harvard.edu/today/

Subscribe to the Harvard Law Today newsletter: https://hls.harvard.edu/sign-up-for-the-harvard-law-today-newsletter-2/